United Therapeutics (UTHR) Azione Prezzo
United Therapeutics Prezzo
Negli ultimi 19 anni United Therapeutics ha aumentato il fatturato del 17,1% all'anno, raggiungendo 3,18 miliardi USD. L'utile per azione è cresciuto del 15,7% all'anno negli ultimi 19 anni. Per United Therapeutics, il margine netto del 41,9% risulta in aumento rispetto al 28,2% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per United Therapeutics è 625,00 USD, circa il 3,9% sopra il prezzo attuale di mercato. Su 22 analisti, 18 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
United Therapeutics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
United Therapeutics Azione e analisi azionaria
Domande frequenti sull'azione United Therapeutics
The business model of United Therapeutics Corp revolves around the development and commercialization of innovative therapies for patients with life-threatening conditions. The company focuses on the research, regulatory approval, manufacturing, and marketing of pharmaceutical products, primarily in the field of pulmonary arterial hypertension (PAH). United Therapeutics Corp collaboratively works with physicians, patients, and regulatory agencies to bring life-saving treatments to the market. By employing a patient-centric approach and leveraging advanced scientific technologies, United Therapeutics Corp aims to provide effective therapeutic options for individuals suffering from PAH and other critical diseases.
United Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of United Therapeutics Corp in the market include companies like Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., and Bayer AG.
United Therapeutics Corp is a leading biotechnology company specializing in the development of innovative therapies for patients with serious medical conditions. Founded in 1996 by Martine Rothblatt, the company has a rich history of pioneering advancements in the field of pulmonary arterial hypertension (PAH) and other rare diseases. United Therapeutics focuses on the research, development, and commercialization of drugs and devices that address the unmet needs of patients worldwide. With a mission to provide hope and improved quality of life, United Therapeutics Corp has successfully introduced several groundbreaking therapies, establishing itself as a trusted global healthcare provider.
Founded in 1996, United Therapeutics Corp has achieved several significant milestones. The company developed Remodulin®, a treatment for pulmonary arterial hypertension (PAH) that received FDA approval in 2002. In the following years, the company successfully launched Tyvaso® and Adcirca®, adding to their portfolio of PAH therapies. Moreover, United Therapeutics Corp pioneered the development of Ex-vivo Lung Perfusion (EVLP) technology, which improves the quality of donor lungs for transplantation. The company's efforts in advancing PAH treatments and lung transplantation techniques have greatly impacted the medical field, making United Therapeutics Corp a global leader in the pharmaceutical industry.
United Therapeutics Corp is primarily present in the United States.
United Therapeutics Corp is committed to delivering innovative solutions in the field of biotechnology. With a strong emphasis on patient care and well-being, the company strives to improve the lives of individuals suffering from severe medical conditions. United Therapeutics Corp's corporate philosophy revolves around cultivating a culture of excellence, fostering a collaborative approach, and maintaining a steadfast dedication to scientific research and development. By consistently pushing boundaries and working towards groundbreaking advancements, United Therapeutics Corp aims to provide hope and transformative therapies for patients worldwide.
Gli analisti fissano attualmente un prezzo obiettivo medio di 635,00 USD per l’azione United Therapeutics (mediana: 625,00 USD), pari a +6,6 % rispetto all’ultimo prezzo. Il consenso si basa su 22 giudizi di analisti.
22 analisti valutano attualmente l’azione United Therapeutics: 18 raccomandano l’acquisto, 3 la tenuta e 1 la vendita. Per il 2026 gli analisti si aspettano per United Therapeutics ricavi pari a 3,18 miliardi USD e un utile per azione di 26,99 USD.
Convertita al tasso di cambio attuale, l’azione United Therapeutics quota 537,23 EUR (601,32 USD).
L’azione United Therapeutics (UTHR) è quotata su 5 borse, tra cui: NASDAQ (UTHR), SIX (Zürich) (UTH.SW), Frankfurt (UTH.F), München (UTH.MU), Düsseldorf (UTH.DU).
United Therapeutics Corp is a leading biotechnology company focused on the development and commercialization of innovative therapies for rare and serious diseases. The company has been pursuing a dual-track strategy since its founding in 1996, which includes both the development of novel drugs and the marketing of already approved products. United Therapeutics' core business focuses on developing drugs for the treatment of lung diseases. The company has specialized particularly in pulmonary hypertension, a rare condition in which high blood pressure in the pulmonary arteries leads to narrowing of the blood vessels and can occur especially in young women. Treatment options for pulmonary hypertension have been limited for a long time, but United Therapeutics has made a breakthrough with its various products. One of United Therapeutics' best-known products is Remodulin, an intravenous medication for the treatment of pulmonary arterial hypertension (PAH) that was already approved in 2002. In addition to Remodulin, the company has also introduced Tyvaso, which is administered as a handheld inhaler and offers patients more flexibility in dosage and application. Another product for the treatment of pulmonary hypertension is Orenitram, an oral medication developed for patients who have difficulty using intravenous medications or inhalers. In addition to developing new drugs, United Therapeutics is also working on further developing and improving existing products. An example of this is the implant for partial lung replacement developed by its subsidiary Lung Biotechnology PBC. The implant contains living cells from a donor lung and is implanted into the body to support the function of the heart-lung system and bridge the time until transplantation. Another focus of United Therapeutics is advancing xenotransplantation, in which organs from animals are to be transplanted into humans. The company has already made significant progress in this field and is closely collaborating with other companies and organizations to further improve this technology. Overall, United Therapeutics' business model is focused on long-term growth and the development of innovative therapies. The company invests heavily in research and development and works closely with customers, partners, and other companies to develop groundbreaking solutions for serious and rare diseases. Through its close collaboration with physicians, research institutes, and patient organizations, the company strives to provide patients worldwide with access to life-saving therapies while also providing its shareholders with solid returns.
Il attesa fatturato di United Therapeutics ammonta a 3,18 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di United Therapeutics ammonta a 1,29 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di United Therapeutics è attualmente 22,28. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione United Therapeutics.
Il rapporto prezzo/fatturato (P/S) di United Therapeutics è attualmente 9,06. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione United Therapeutics.
Il Quality Score AlleAktien per United Therapeutics è 7/10.
L'ISIN di United Therapeutics è US91307C1027. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di United Therapeutics è 923818. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di United Therapeutics è UTHR. Con questo simbolo di borsa vengono negoziate le azioni United Therapeutics in borsa.
Azione United Therapeutics
Gruppo di pari di United Therapeutics
United Therapeutics Ticker
United Therapeutics FIGI
Altre metriche e analisi di United Therapeutics in Deep Dive.
La nostra analisi azionaria dell'azione United Therapeutics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di United Therapeutics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: